Sales of Hough Pharma’s over the counter COVID-19 Home Test have surged in their first week on shelves
across the country.
Less than three weeks after the Therapeutic Good Administration approved the test, which can be done at
home, demand for the product is outstripping supply.
The simple test involves a nasal swab that is mixed with a buffer liquid, which is applied to a test cassette.
Within 15 minutes, the test reveals whether you have tested negative to the virus or you have it in your
system.
The Hough Pharma COVID-19 Home Test is already available on-line and through selected Coles,
Woolworths, independent supermarkets, convenience stores and petrol stations across Australia.
“We’re working hard to keep up with demand for the product. Our team are working around the clock to get
the tests into as many stores as possible,” said Hough Pharma CEO, Greg Hough.
“Over the coming week, Hough Pharma Home Test will deliver more than 750,000 tests to over 8,500 retail
outlets across Australia including to regional and rural communities from the Northern Territory to
Tasmania.”
“At less than $15 a test, they are available and affordable to everyone,” Mr Hough said.
“We believe rapid antigen tests are an essential tool in the continued fight against this pandemic.”
Our tests will allow communities right across Australia to continue to stay open and keep people safely working, particularly in high-risk
settings like healthcare, schools and hotspots which is critical for our economy as well as our health and
wellbeing.”
“As we know, even fully vaccinated people can carry and transmit the virus to others.”
When used in conjunction with its Hough Home App, employees can create a testing certificate to
demonstrate a negative result that can satisfy their employers they are safe to attend work.
Those who return a positive result will still need to immediately self-isolate, undergo a PCR test and consult
the health authorities in their state or territory to keep themselves, their family, workmates and community
safe.
Hough Pharma and its manufacturing partner Biohit healthcare are ramping up manufacture, with production
now tracking at more than 2 million tests a week to meet demand in Australia over the next three months.
The tests are available for self-testing to detect possible infection with SARS-CoV-2 (COVID-19) in adults and
children aged seven years and older.
